Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.17USD
1:30am IST
Change (% chg)

$-0.74 (-8.31%)
Prev Close
$8.91
Open
$8.95
Day's High
$9.07
Day's Low
$8.14
Volume
93,069
Avg. Vol
158,472
52-wk High
$14.00
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

06 Sep 2018

UPDATE 2-Maryland charges Insys with engaging in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

06 Sep 2018

Maryland charges Insys engaged in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with having engaged in deceptive practices that resulted in a powerful opioid medication the drugmaker produced that was meant for cancer patients being prescribed to other people.

06 Sep 2018

REFILE-UPDATE 3-Insys to pay $150 mln to settle U.S. opioid kickback probe

Aug 8 Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

08 Aug 2018

Insys to pay $150 million to settle U.S. opioid kickback probe

Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

08 Aug 2018

Insys to pay $150 mln to settle DoJ probe

Aug 8 Insys Therapeutics said on Wednesday it had reached an agreement in principle with the U.S. Department of Justice to settle a civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

08 Aug 2018

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

27 Jul 2018

UPDATE 1-FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

27 Jul 2018

FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration had declined to approve its opioid painkiller, citing potential safety concerns.

27 Jul 2018

U.S. to narrow opioid bribe case against Insys founder, others

BOSTON U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them.

25 Jul 2018

Earnings vs. Estimates